{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"22.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification.","dispersionType":"Full Range","groups":[{"description":"Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent","id":"OG000","title":"Zanubrutinib"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis set consisted of all participants with a confirmed diagnosis of MZL who received at least 1 dose of study drug; DOR was summarized for responders only, defined as participants with a best overall response of partial response or above.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 2.5 months","title":"Duration of Response (DOR) by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}